VIYASHViyash Scientific Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹8,730 Cr
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
6 / 100
+5 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in balance sheet stress. No immediate concerns are visible. Risk is increasing at a faster pace.

15.2th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹249.95▼0.18%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+8.0 pts
Stability Adjustment
-2.0 pts
Final Composite Risk6 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 10 → 6 over 13 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Working Capital Expansion
What to Watch Next Quarter
  • Inventory turnover
  • Operating profit margins
  • Working capital efficiency

Active Risk Objects (6)

CriticalHigh
Inventory Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight15/15
MomentumDecaying
Last SignalQ4 FY2024
Inventory growth (0.0%) significantly outpaced revenue growth (-0.9%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Negative FCF Streak
⚖️ Governance SignalsAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2024
VIYASH: Negative Free Cash Flow for last 3 consecutive years.

"Free cash flow pressure is easing as capital intensity or working capital stress recedes."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 3 Years
More Detail
Impact Weight10/15
MomentumPersistent
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 24.0%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ2 FY2026
VIYASH: Raw material costs consumed an additional 3.5% of revenue YoY.

"Early signs of margin erosion. Input costs are beginning to eat into core profits."

Low Interest Coverage
💧 Liquidity & CoverageQuarterlyActive for 8 Qtrs
More Detail
Impact Weight8/15
MomentumDecaying
Last SignalQ4 FY2025
VIYASH: Low Interest Coverage Ratio of 2.08x in FY2025 Q4 (Threshold: 2.5x).

"The ability to cover interest is strengthening as earnings improve or debt is retired."

Revenue-Debt Divergence
🏛️ Solvency & LeverageAnnualActive for 1 Years
More Detail
Impact Weight6/15
MomentumDecaying
Last SignalFY2024
VIYASH: Revenue fell 3.3% while Debt rose 13.4% in 2024 vs 2023.

"Debt servicing metrics have improved recently. The company is actively deleveraging."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)3.177.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+60.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹249.95(-0.18%)
1M Divergence+20.41%
1 Week-2.88%
1 Month+22.68%
6 Months+20.5%
1 Year+26.43%
2 Year+141.61%
3 Year+239.15%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Strategic vigilance is advised as structural decay is accelerating.

VIYASH • MARKET STRUCTURE

Stage 2 — Advancing

The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.

Stage Transition Prob.98%
Trend QualityStrong
Phase Progression
Phase Progression Score75%
Readiness LabelHigh (Phase Transition Imminent)
Probability of Advancing98%
CoinTree Momentum
Composite Z-Score+0.7491σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#326 of 2716
Top 12.00% in momentum strength
Timeframe Sparklines
1W-2.9%
1M+22.7%
6M+20.5%
Weinstein Indicators
150 DMA₹212.15
200 DMA₹206.43
150 DMA Slope+2.0822%Rising
Relative Strength+25.99%Leading
Relative Turnover (RTR)2.0971
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

VIYASHViyash Scientific Limited
6 Risk
Sector %ile15th
Delta+5
Active Flags6
Accel+1
Balance Sheet Stress

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
660th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Working Capital Expansion

2026

Industrial Margin Stress

2025

Working Capital Expansion

2024

Inventory Stress

2024

Working Capital Expansion

2024

Negative FCF Streak

2024

Revenue-Debt Divergence

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20263,464225323436
FY20251,5663283446
FY20241,381-3031451
FY20231,427-12217398